Search
Lund based BioInvent has had a busy week with a presentation of one program in ovarian cancer at ASCO, and two more coming up in hematological cancers at the upcoming EHA Congress
Chief Scientific Officer Björn Frendéus walks us through the companies antibody discovery platform, and the two lead clinical assets, which target TNFR2 and FcγRIIB.
Jun 9
.png){kind=logo}